In the studies included in such systematic review, the amount of CD133+ and Nestin+ cells in human gliomas ranged between 0.5 and over 82% and between 1–100%, respectively (Arai et al., 2012; Hatanpaa et al., 2014; Kase et al., 2013; Kim et al., 2011; Melguizo et al., 2012; Wan et al., 2011). The gene discussed is NES; the disease is central nervous system cancer.